Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | ESRRB | O95718 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15925822 | 0.93 | SMN1; SMN2 (0.43) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 | |
| SCHEMBL15908927 | 0.88 | PDK2 (0.38) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 | |
| SCHEMBL15948180 | 0.84 | PDK2 (0.36) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 | |
| SCHEMBL9932966 | 0.84 | PDK2 (0.40) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 | |
| Iodide SCHEMBL9933682 | 0.83 | GPR119 (0.42) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 | |
| SCHEMBL15875834 | 0.81 | SMN1; SMN2 (0.40) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 | |
| SCHEMBL15875811 | 0.81 | PDK2 (0.38) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 | |
| Iodide SCHEMBL13386315 | 0.80 | PDK2 (0.40) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 | |
| SCHEMBL13386221 | 0.78 | SMN1; SMN2 (0.38) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 | |
| SCHEMBL15875889 | 0.78 | MAPT (0.46) | MEN1KMT2ASMN1; SMN2CYP2C19GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| US-9382221-B2 | Compounds, compositions, and methods for treating alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Prosetta Antiviral, Inc. | 2014-10-23 | — | — | US | disclosed |
| US-8796448-B1 | Compounds, compositions, and methods for treating Alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2014-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | PSEN1, APP, PSEN2 | MEN1 1540/4885KMT2A 257/4885SMN1; SMN2 786/4885 |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN1, APP, PSEN2 | MEN1 1540/4885KMT2A 257/4885SMN1; SMN2 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.